The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, which both contain the active ingredient semaglutide and are approved by the U.S. Food and Drug Administration to treat Type 2 diabetes and obesity, respectively.

It is the crown case that Ms Hawes, a prescribing nurse, supplied different types of prescription only medicines including weight loss drugs, facial fillers and drugs used for local anaesthesia. The fraud offences accuse Hawes of filling in prescriptions with the names of people "for whom no treatment was being given".

Health experts are investigating a possible link between popular weight loss drugs like Ozempic and sudden blindness.

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial of its experimental drug CagriSema — a combination of semaglutide and a medicine called cagrilintide. People on CagriSema lost about 23% of their body weight in a 68-week study, outperforming both drugs when taken alone.

The telehealth company Hims & Hers put out a Super Bowl ad that skimped on clarifying that its compounded semaglutide medications aren't FDA-approved.

Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived deal for consumers.

Telehealth company Hims & Hers is pushing the boundaries of drug compounding and testing the limits of regulators.

The ad from the telehealth company Hims & Hers promoted the company’s compounded weight loss drugs. The ad portrayed the obesity epidemic as a rigged game because of the greedy health care system. Dr.